PROCEPT BioRobotics (PRCT) Competitors

Stevanato Group (NYSE:STVN) and PROCEPT BioRobotics (NASDAQ:PRCT) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.

Which has more risk & volatility, STVN or PRCT?

Stevanato Group has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500. Comparatively, PROCEPT BioRobotics has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500.

Is STVN or PRCT more profitable?

Stevanato Group has a net margin of 11.73% compared to PROCEPT BioRobotics' net margin of -30.60%. Stevanato Group's return on equity of 10.34% beat PROCEPT BioRobotics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stevanato Group	11.73%	10.34%	6.21%
PROCEPT BioRobotics	-30.60%	-23.73%	-17.34%

Does the media refer more to STVN or PRCT?

In the previous week, PROCEPT BioRobotics had 9 more articles in the media than Stevanato Group. MarketBeat recorded 23 mentions for PROCEPT BioRobotics and 14 mentions for Stevanato Group. Stevanato Group's average media sentiment score of 0.55 beat PROCEPT BioRobotics' score of -0.06 indicating that Stevanato Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stevanato Group	7 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
PROCEPT BioRobotics	1 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has preferable earnings & valuation, STVN or PRCT?

Stevanato Group has higher revenue and earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stevanato Group	€1.19B	5.67	€127.45M	€0.54	41.39
PROCEPT BioRobotics	$224.50M	10.01	-$91.41M	-$1.55	-26.05

Do institutionals and insiders believe in STVN or PRCT?

89.5% of PROCEPT BioRobotics shares are owned by institutional investors. 17.4% of PROCEPT BioRobotics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Do analysts recommend STVN or PRCT?

PROCEPT BioRobotics has a consensus price target of $74.88, indicating a potential upside of 85.43%. Given PROCEPT BioRobotics' higher probable upside, analysts clearly believe PROCEPT BioRobotics is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stevanato Group	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.83
PROCEPT BioRobotics	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

Summary

Stevanato Group beats PROCEPT BioRobotics on 10 of the 17 factors compared between the two stocks.